Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Radiogenomic Profiling of Dendritic Cells and Macrophages to Predict Recurrence in Colorectal Liver Metastasis (RaP-DMac-LiMe)

4 augusti 2026 uppdaterad av: Famularo Simone, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

The RaP-DMac-LiMe study (Radiogenomic Profiling of Dendritic Cells and Macrophages to Predict Recurrence in Colorectal Liver Metastasis) is a monocentric, non-profit observational study promoted by Fondazione Policlinico Universitario A. Gemelli IRCCS. Its primary aim is to identify immunological, genomic, and radiomic biomarkers associated with recurrence risk in patients with colorectal liver metastases (CRLM) undergoing curative-intent liver resection.

The study is based on the need to improve prognostic stratification in CRLM by integrating information from the tumor immune microenvironment, tumor genomics, radiomics, and clinical data. Particular attention is given to myeloid immune cells, especially dendritic cells and tumor-associated macrophages, whose role in metastatic progression and recurrence remains insufficiently understood.

The primary objective is to assess the association between myeloid immune profiles and recurrence risk through integrated molecular, spatial, genomic, and radiological analyses. Secondary objectives include characterizing the transcriptomic and genomic features of dendritic cells and macrophages, identifying radiomic and circulating tumor DNA (ctDNA) biomarkers, and evaluating their potential as non-invasive tools for recurrence prediction and patient stratification.

The study includes a retrospective cohort of approximately 160 patients treated between 2009 and 2023 and a prospective cohort of approximately 50 patients who will be followed for 24 months. Tumor tissue samples, peripheral blood, imaging data (CT/MRI), and clinical information collected during routine care will be analyzed without introducing any experimental interventions or deviations from standard clinical practice.

Analyses will include transcriptomic profiling, multiplex spatial characterization of immune cells, circulating tumor DNA sequencing using next-generation sequencing technologies, radiomic feature extraction, and integration of all data using statistical and machine learning approaches. Predictive models will be trained on retrospective data and independently validated in the prospective cohort.

The primary endpoint is the prediction of colorectal liver metastasis recurrence within two years after liver resection. Ultimately, the study aims to develop and validate a multimodal predictive model integrating immune, genomic, radiomic, and clinical variables to improve recurrence risk assessment and support personalized patient management.

The overall study duration is 36 months. All procedures will be conducted in accordance with ethical standards and data protection regulations, with samples and clinical data pseudonymized and handled in compliance with the GDPR.

Studieöversikt

Studietyp

Observationell

Inskrivning (Beräknad)

210

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Adult patients with metastatic colorectal cancer and histologically confirmed colorectal liver metastases undergoing standard clinical management and curative-intent liver resection at Fondazione Policlinico Universitario A. Gemelli IRCCS. The study includes both a retrospective cohort with available tumour tissue and clinical data and a prospective cohort undergoing collection of tumour tissue and peripheral blood samples during routine clinical care

Beskrivning

Inclusion Criteria:

  • Age ≥18 years.
  • Histologically confirmed colorectal liver metastases.
  • Administration of neoadjuvant chemotherapy prior to liver resection, with objective tumour response classified as partial response (PR) or stable disease (SD) according to RECIST criteria.
  • Availability of a hepatobiliary contrast-enhanced MRI performed within 2 months before surgery.
  • Provision of informed consent for prospectively enrolled participants, or eligibility under Article 110-bis of the Italian Privacy Code for retrospectively enrolled participants.

Exclusion Criteria:

  • Recurrent metastatic disease.
  • Liver resection performed with non-curative intent.
  • Current or previous hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
  • Concomitant malignancies or history of another malignancy treated within the previous 5 years.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Retrospective CRLM Cohort
Patients with histologically confirmed colorectal liver metastases who underwent curative-intent liver resection between January 2009 and December 2023 and for whom tumour tissue and clinical data are available. Retrospective collection and analysis of tumour tissue, radiological, genomic, immune and clinical data.
Analysis of tumour tissue, radiological images, and clinical data collected during routine clinical care. Molecular, genomic, spatial, transcriptomic, and radiomic profiling will be performed to investigate associations with recurrence risk and clinical outcomes in patients with colorectal liver metastases. No investigational drugs, devices, or experimental procedures are administered as part of the study.
Prospective CRLM Cohort
Patients with histologically confirmed colorectal liver metastases undergoing standard clinical management and curative-intent liver resection, enrolled prospectively with collection of tumour tissue and peripheral blood samples. Prospective collection and analysis of tumour tissue, peripheral blood-derived ctDNA, radiological, genomic, immune and clinical data.
Patients with histologically confirmed colorectal liver metastases undergoing standard clinical management and curative-intent liver resection, enrolled prospectively with collection of tumour tissue and peripheral blood samples. Prospective collection and analysis of tumour tissue, peripheral blood-derived ctDNA, radiological, genomic, immune and clinical data.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Prediction of Colorectal Liver Metastasis Recurrence
Tidsram: 24 Months after liver resection
Prediction of colorectal liver metastasis recurrence following curative-intent liver resection using an integrated model based on radiogenomic, immune, and clinical profiling. Recurrence will be assessed through routine clinical follow-up and radiological evaluation.
24 Months after liver resection

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Genomic Alterations Associated With Immune Landscape Patterns
Tidsram: Baseline (analysis of collected tumour tissue and ctDNA samples)
Identification of tumour-associated genetic alterations correlated with specific immune microenvironment profiles in colorectal liver metastases.
Baseline (analysis of collected tumour tissue and ctDNA samples)
Radiomic Features Associated With Immune Cell Distribution
Tidsram: Baseline (pre-operative MRI/CT imaging)
Identification of radiomic features associated with the distribution and characteristics of dendritic cells and tumour-associated macrophages within tumour tissues.
Baseline (pre-operative MRI/CT imaging)
Performance of the Machine Learning-Based Recurrence Prediction Model
Tidsram: Up to 24 Months after liver resection
Development and validation of a machine learning-based model for recurrence risk prediction. Model performance will be assessed using area under the receiver operating characteristic curve (AUC), sensitivity, specificity, positive predictive value, and negative predictive value.
Up to 24 Months after liver resection
Correlation Between Myeloid Immune Cell Frequencies and Clinical Outcome Measures
Tidsram: Up to 24 Months after liver resection
Correlation between dendritic cell and tumor-associated macrophage frequencies (% of CD45⁺ immune cells), measured by multiparametric flow cytometry, and overall survival (months), relapse-free survival (months), and recurrence status (yes/no).
Up to 24 Months after liver resection

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Simone Famularo, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 september 2026

Primärt slutförande (Beräknad)

1 september 2029

Avslutad studie (Beräknad)

31 december 2029

Studieregistreringsdatum

Först inskickad

29 juli 2026

Först inskickad som uppfyllde QC-kriterierna

29 juli 2026

Första postat (Faktisk)

4 augusti 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

6 augusti 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

4 augusti 2026

Senast verifierad

1 augusti 2026

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera